Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change...

7
ALLOSTERIC INHIBITORS Group Red – Demacia Gabe, Chris, Tom

Transcript of Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change...

Page 1: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

ALLOSTERIC INHIBITORS

Group Red – Demacia

Gabe, Chris, Tom

Page 2: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

ALLOSTERIC ENZYMES- Enzymes with more than one

polypeptide chain can change between an active shape and an inactive shape

- When the body needs to slow down a reaction, it bonds an allosteric inhibitor to a site on the enzyme that locks it into its inactive shape

Page 3: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

ALLOSTERIC INHIBITOR An allosteric inhibitor is the substance that binds to an enzyme to make its active sites inactive

Page 4: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.
Page 5: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

ALLOSTERIC INHIBITORSAn allosteric inhibitor

is a molecule that binds to enzymes and helps decrease their activity. Since these inhibitors molecules block an enzyme’s activity it can kill a pathogen or correct a metabolic imbalance in the body. Many drugs are enzyme inhibitors.

Page 6: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

Allosteric inhibition of the protein tyrosine phosphatase-1B (PTP1B) prevents formation of the active conformation of the enzyme by blocking mobility of the catalytic loop, according to research published in the August issue of Nature Structural and Molecular Biology. PTP1B is an attractive target for the therapeutic intervention of metabolic syndromes such as type 2 diabetes and obesity — states that show hallmark resistance to the hormones insulin and leptin — because it is a negative regulator of the relevant hormone receptors. The catalytic site of PTP1B has so far proven intractable to small-molecule drugs, making allosteric inhibition an appealing strategy. http://www.nature.com/drugdisc/res_high/articles/nrd1504.html

Page 7: Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.

Videos Feedback Inhibition of Biochemical

Pathways http://www.youtube.com/watch?v=c8FcZVJS1Q8&feature=related

Enzyme Regulation (long video 20min)http://www.youtube.com/watch?v=nMEbvlHGB4A